Energy deficit in Huntington disease: why it matters.

Huntington disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models. Here we review the clinical, biochemical, and molecular evidence of an energy deficit in HD and discuss the mechanisms underlying mitochondrial and related alterations.

[1]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[2]  G. Bates,et al.  A Large Number of Protein Expression Changes Occur Early in Life and Precede Phenotype Onset in a Mouse Model for Huntington Disease*S , 2009, Molecular & Cellular Proteomics.

[3]  A. Orr,et al.  Impaired mitochondrial trafficking in Huntington's disease. , 2010, Biochimica et biophysica acta.

[4]  M. Beal,et al.  Oxidative Stress in Huntington's Disease , 1999, Brain pathology.

[5]  L. Tretter,et al.  Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[6]  M. Beal,et al.  Impaired PGC-1 a function in muscle in Huntington’s disease , 2009 .

[7]  M. Beal,et al.  Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease , 2003, Journal of neurochemistry.

[8]  A. Ochoa,et al.  Assessment of the nutrition status of patients with Huntington's disease. , 2004, Nutrition.

[9]  Anil Kumar,et al.  Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms , 2006, Behavioural pharmacology.

[10]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[11]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[12]  M. Beal,et al.  Oxidative damage in Huntington's disease pathogenesis. , 2006, Antioxidants & redox signaling.

[13]  J. Caviston,et al.  Huntingtin facilitates dynein/dynactin-mediated vesicle transport , 2007, Proceedings of the National Academy of Sciences.

[14]  Ole A. Andreassen,et al.  Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.

[15]  J. Pedraza-Chaverri,et al.  Comparative Analysis of Superoxide Dismutase Activity between Acute Pharmacological Models and a Transgenic Mouse Model of Huntington's Disease , 2001, Neurochemical Research.

[16]  Paolo Guidetti,et al.  Early Degenerative Changes in Transgenic Mice Expressing Mutant Huntingtin Involve Dendritic Abnormalities but No Impairment of Mitochondrial Energy Production , 2001, Experimental Neurology.

[17]  Ian J. Reynolds,et al.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons , 2006, Neurobiology of Disease.

[18]  T. D. de Koning,et al.  Fatal cerebral edema associated with serine deficiency in CSF , 2010, Journal of Inherited Metabolic Disease.

[19]  J. Roh,et al.  Slowed progression in models of huntington disease by adipose stem cell transplantation , 2009, Annals of neurology.

[20]  Roger A. Barker,et al.  The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study , 2008, Experimental Neurology.

[21]  D. Nicholls.  Mitochondrial calcium function and dysfunction in the central nervous system. , 2009, Biochimica et biophysica acta.

[22]  J. Andrich,et al.  PGC-1alpha as modifier of onset age in Huntington disease , 2009, Molecular Neurodegeneration.

[23]  Yohanns Bellaiche,et al.  Huntingtin Is Required for Mitotic Spindle Orientation and Mammalian Neurogenesis , 2010, Neuron.

[24]  T. Wallimann,et al.  Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. , 1996, Biochimica et biophysica acta.

[25]  G. Johnson,et al.  Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin* , 2005, Journal of Biological Chemistry.

[26]  B. Landwehrmeyer,et al.  Low stability of huntington muscle Mitochondria against Ca2+ in R6/2 mice , 2006, Annals of neurology.

[27]  Lu Gan,et al.  Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. , 2005, Human molecular genetics.

[28]  Alexandra Durr,et al.  Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.

[29]  E. Ravussin,et al.  Higher sedentary energy expenditure in patients with Huntington's disease , 2000, Annals of neurology.

[30]  F. Condé,et al.  Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat , 1998, Journal of neurochemistry.

[31]  M. Beal,et al.  Impaired PGC-1alpha function in muscle in Huntington's disease. , 2009, Human molecular genetics.

[32]  J. Hodgson,et al.  Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.

[33]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[34]  M. MacDonald,et al.  Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. , 2000, Human molecular genetics.

[35]  C. Epstein,et al.  Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase , 1995, Nature Genetics.

[36]  P. Swanson,et al.  Biochemical abnormalities in Huntington's chorea brains , 1974, Neurology.

[37]  Christian Néri,et al.  Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons , 2005, Nature Genetics.

[38]  T. Videen,et al.  Selective defect of in vivo glycolysis in early Huntington's disease striatum , 2007, Proceedings of the National Academy of Sciences.

[39]  J C Mazziotta,et al.  Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.

[40]  J. Nevins,et al.  Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription* , 2002, The Journal of Biological Chemistry.

[41]  R. Roos,et al.  Characterization and localization of the Huntington disease gene product. , 1993, Human molecular genetics.

[42]  J. Caviston,et al.  Huntingtin as an essential integrator of intracellular vesicular trafficking. , 2009, Trends in cell biology.

[43]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[44]  M. MacDonald,et al.  Huntingtin interacts with a family of WW domain proteins. , 1998, Human molecular genetics.

[45]  M. MacDonald,et al.  The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. , 2001, Human molecular genetics.

[46]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[47]  O. Andreassen,et al.  Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. , 2001, Neurobiology of disease.

[48]  Jacqueline K. White,et al.  Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion , 1997, Nature Genetics.

[49]  M. Hayden,et al.  Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors , 2006, The Journal of Neuroscience.

[50]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[51]  H. Herzog,et al.  Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease , 1993, Journal of Neurology.

[52]  B. Landwehrmeyer,et al.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[53]  Sarah J Tabrizi,et al.  Gene expression in Huntington's disease skeletal muscle: a potential biomarker. , 2005, Human molecular genetics.

[54]  B R Rosen,et al.  Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. , 1993, Neurology.

[55]  A H Schapira,et al.  Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse , 2000, Annals of neurology.

[56]  S. Browne,et al.  Mitochondria and Huntington's Disease Pathogenesis , 2008, Annals of the New York Academy of Sciences.

[57]  Shihua Li,et al.  HAP1 and intracellular trafficking. , 2005, Trends in pharmacological sciences.

[58]  B. Bloem,et al.  Weight loss in neurodegenerative disorders , 2008, Journal of Neurology.

[59]  Xiao-Jiang Li,et al.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.

[60]  J. Oliveira.  Nature and cause of mitochondrial dysfunction in Huntington’s disease: focusing on huntingtin and the striatum , 2010, Journal of neurochemistry.

[61]  A. Barrientos,et al.  Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. , 2006, Human molecular genetics.

[62]  D. Wallace,et al.  A mitochondrial paradigm for degenerative diseases and ageing. , 2001, Novartis Foundation symposium.

[63]  S. Hersch,et al.  Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice , 2003, Journal of neurochemistry.

[64]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[65]  Å. Petersén,et al.  Hypothalamic–endocrine aspects in Huntington's disease , 2006, The European journal of neuroscience.

[66]  D. Rubinsztein,et al.  Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease , 2001, Journal of medical genetics.

[67]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[68]  P. Puigserver,et al.  Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.

[69]  M. MacDonald,et al.  HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.

[70]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[71]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[72]  H. Fibiger,et al.  Body weight, feeding, and drinking behaviors in rats with kainic acid-induced lesions of striatal neurons—With a note on body weight symptomatology in Huntington's disease , 1979, Experimental Neurology.

[73]  K. Hoyt,et al.  Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[74]  N. Déglon,et al.  Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.

[75]  Rolf Gruetter,et al.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo1H NMR spectroscopy , 2007, Journal of neurochemistry.

[76]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[77]  G. Johnson,et al.  Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells , 2008, Journal of Biological Chemistry.

[78]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[79]  Jiandie D. Lin,et al.  Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice , 2004, Cell.

[80]  E. Seeberg,et al.  Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro , 2004, Molecular and Cellular Biology.

[81]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[82]  E. Hirsch,et al.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. , 2006, Molecular biology of the cell.

[83]  S. Humbert,et al.  The biology of Huntington's disease. , 2008, Handbook of clinical neurology.

[84]  M. MacDonald,et al.  Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. , 2003, Human molecular genetics.

[85]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.

[86]  D. Sax,et al.  Factors associated with slow progression in Huntington's disease. , 1991, Archives of neurology.

[87]  Chris Frost,et al.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.

[88]  S. Luquet,et al.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.

[89]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[90]  F. Casanueva,et al.  Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.

[91]  M. Beal,et al.  The Energetics of Huntington's Disease , 2004, Neurochemical Research.

[92]  A. Blamire,et al.  High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study , 2005, Neurology.

[93]  L. Raymond,et al.  Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.

[94]  K. Marder,et al.  Weight loss in early stage of Huntington’s disease , 2002, Neurology.

[95]  Christoph Handschin,et al.  Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.

[96]  Yih-Ru Wu,et al.  Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. , 2007, Biochemical and biophysical research communications.

[97]  A. Durr,et al.  Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease , 2010, European Journal of Human Genetics.

[98]  P. Brundin,et al.  Beyond the brain: widespread pathology in Huntington's disease , 2009, The Lancet Neurology.

[99]  Elena Cattaneo,et al.  Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.

[100]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[101]  S. Snyder,et al.  p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease , 2005, Neuron.

[102]  D. Butterfield,et al.  3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease , 2000, Brain Research.

[103]  S. Snyder,et al.  Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity , 2009, Science.

[104]  D. Manners,et al.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy , 2000, Annals of neurology.

[105]  S. Swinnen,et al.  Creatine supplementation in Huntington’s disease , 2003, Neurology.

[106]  M. Brini,et al.  Calcium Homeostasis and Mitochondrial Dysfunction in Striatal Neurons of Huntington Disease* , 2008, Journal of Biological Chemistry.

[107]  He Li,et al.  N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking , 2008, The Journal of Neuroscience.

[108]  S. Tabrizi,et al.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.

[109]  M. MacDonald,et al.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.

[110]  M. Portero-Otín,et al.  Protein Targets of Oxidative Damage in Human Neurodegenerative Diseases with Abnormal Protein Aggregates , 2010, Brain pathology.

[111]  H. Fukui,et al.  Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates. , 2007, Human molecular genetics.

[112]  M. Beal,et al.  Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease , 2010, Experimental Neurology.

[113]  R. Richards,et al.  Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. , 2007, Human molecular genetics.

[114]  M. Beal,et al.  Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases , 2009, Journal of neurochemistry.

[115]  M. Chesselet,et al.  Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. , 2009, Human molecular genetics.

[116]  H. Fibiger,et al.  BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS , 1981, The Medical journal of Australia.

[117]  Erich E Wanker,et al.  The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.

[118]  D. Rubinsztein,et al.  Huntington's disease: from pathology and genetics to potential therapies. , 2008, The Biochemical journal.

[119]  M. Beal,et al.  Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. , 2010, Human molecular genetics.

[120]  P. R. Gardner,et al.  Superoxide Radical and Iron Modulate Aconitase Activity in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[121]  I. Ferrer,et al.  Proteomic and oxidative stress analysis in human brain samples of Huntington disease. , 2008, Free radical biology & medicine.

[122]  J. Caboche,et al.  Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments , 2008, Current opinion in neurology.

[123]  G. Rebec,et al.  Ascorbate treatment attenuates the Huntington behavioral phenotype in mice , 2003, Neuroreport.

[124]  Jaclyn I. Wamsteeker,et al.  Increased metabolism in the R6/2 mouse model of Huntington’s disease , 2008, Neurobiology of Disease.

[125]  A. Cooper,et al.  The selective vulnerability of striatopallidal neurons , 1999, Progress in Neurobiology.